Viatris upgraded by Jefferies with a new price target
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies upgraded Viatris from Hold to Buy and set a new price target of $15.00 from $13.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2024 | $15.00 | Buy | Jefferies |
| 10/23/2023 | $13.00 → $9.00 | Neutral → Underperform | BofA Securities |
| 6/23/2023 | $11.00 | Equal Weight → Underweight | Barclays |
| 4/24/2023 | $11.00 | Overweight → Equal Weight | Barclays |
| 2/17/2023 | $16.00 → $14.00 | Outperform → Market Perform | BMO Capital Markets |
| 1/27/2023 | $13.00 → $15.00 | Hold → Buy | Jefferies |
| 11/10/2022 | $9.00 → $12.00 | Sell → Neutral | UBS |
| 11/8/2022 | $10.00 | Underweight → Neutral | Piper Sandler |
Jefferies resumed coverage of Viatris with a rating of Buy and set a new price target of $15.00
BofA Securities downgraded Viatris from Neutral to Underperform and set a new price target of $9.00 from $13.00 previously
Barclays downgraded Viatris from Equal Weight to Underweight and set a new price target of $11.00
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G - Viatris Inc (0001792044) (Subject)
144 - Viatris Inc (0001792044) (Subject)
10-Q - Viatris Inc (0001792044) (Filer)
8-K - Viatris Inc (0001792044) (Filer)
PITTSBURGH, Nov. 7, 2024 /PRNewswire/ -- Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1] Strong New Product Revenues of $133 Million Drove Growth Across Segments U.S. GAAP Net Earnings were $95 Million; Adjusted EBITDA Grew ~4% to $1.3 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was $0.08 per Share; Adjusted EPS Grew ~6% to $0.75 per Share on a Divestiture-Adjusted Basis[2] Repaid ~$1.9 Billion of Debt, Expects to Achieve its Long-Term Gross Leverage Target of ~3.0x by end of the Year[3] Entered into Exclusive Licensing Agreement for
PITTSBURGH, Nov. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of business on November 22, 2024. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we p
PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List. This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider. "At Viatris, diverse perspectives drive innovation and our ability to make an impact, as we empower people worldwide to live healthier at every stage of life," said Andrew Enrietti, Chief People Officer, Viatris. "Being recognized on Forbes' list of the World's Top Companies for Women 2024 demonstrates our focus on investing in our people and fostering diverse talent. This accolade
These ten large-cap stocks were the best performers in the last week. Are they in your portfolio? Warner Bros. Discovery, Inc. (NASDAQ:WBD) stock escalated 18.28% after a report that the company had discussed plans to split its digital streaming and studio businesses from its legacy television networks. MicroStrategy Inc.’s (NASDAQ:MSTR) stock gained 16.74% last week amid a rise in Bitcoin’s price. D.R. Horton, Inc. (NYSE:DHI) shares surged 12.91% after the company reported better-than-expected Q3 financial results and revised FY24 guidance. The company also authorized a new $4 billion share repurchase. Few analysts raised the price forecasts on the stock. Coinbase Global Inc.’s
Jefferies analyst Glen Santangelo reinstates Viatris (NASDAQ:VTRS) with a Buy and announces $15 price target.
The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated retractable disease in Japan, with an estimated 33,000 patients in Japan* assumed to be suffering from this disease and with limited treatment options for IgAN patients in this country.
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
PITTSBURGH, Nov. 7, 2024 /PRNewswire/ -- Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1] Strong New Product Revenues of $133 Million Drove Growth Across Segments U.S. GAAP Net Earnings were $95 Million; Adjusted EBITDA Grew ~4% to $1.3 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was $0.08 per Share; Adjusted EPS Grew ~6% to $0.75 per Share on a Divestiture-Adjusted Basis[2] Repaid ~$1.9 Billion of Debt, Expects to Achieve its Long-Term Gross Leverage Target of ~3.0x by end of the Year[3] Entered into Exclusive Licensing Agreement for
PITTSBURGH, Nov. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of business on November 22, 2024. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we p
PITTSBURGH, Sept. 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report its third quarter 2024 financial results on Thursday, November 7, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the tradit
PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors. "We are pleased to welcome Dr. Vivaldi to our Board of Directors," said Melina Higgins, Chair of the Board, Viatris. "We believe his proven expertise and long track record of success will enhance the efforts of the Board across a range of areas, in particular with regards to our Science and Technology Commit
PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific background and experience across multiple markets and therapeutic areas. Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology
Company thanks Sanjeev Narula for his role in the successful execution of Viatris' Phase 1 strategy; Narula will support a smooth CFO transition prior to his departure on March 1, 2024 PITTSBURGH, Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that, as it prepares to enter Phase 2 of its strategic plan, Theodora "Doretta" Mistras has been appointed Chief Financial Officer (CFO) effective March 1, 2024, and Philippe Martin has been appointed Chief R&D Officer with immediate effect. Current Viatris CFO Sanjeev Narula, who h
4 - Viatris Inc (0001792044) (Issuer)